Press release
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments
Total revenues, which consist primarily of net product revenues and collaboration revenues, for the fourth quarter and full-year 2021 totaled $201.5 million
About this update from Sarepta Therapeutics, Inc.
[{"type":"text","content":"Total revenues, which consist primarily of net product revenues and collaboration revenues, for the fourth quarter and full-year 2021 totaled $201.5 million and $701.9 million, respectivelyNet product revenues for the fourth quarter and full-year 2021 totaled $178.7 million and $612.4 million, respectively Fourth quarter 2021 net product revenues increased approximately 46% over the fourth quarter of 2020; full-year 2021 net product revenues increased approximately 34% over the prior year CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2021. “In 2021, Sarepta distinguished itself as a well-funded, fully integrated, commercial-stage biotech that executes against its ambitious goals. Launching our third RNA-based therapy, AMONDYS 45®(casimersen) in 2021, we enjoyed our 21st straight quarter of strong quarter-over-quarter growth. In the fourth quarter of 2021, total revenues reached $201.5 million and net product revenue for our now three RNA-based therapies reached $178.7 million, a 46% increase over the same quarter of the prior year. For full-year 2021, total revenue reached $701.9 million and net product revenue was $612.4 million, a 34% increase over the prior year. In 2021, we also commenced pivotal trials for our lead candidates in both our RNA and our gene therapy platforms. We initiated Part B of the MOMENTUM study, our global pivotal trial of SRP-5051, our next-generation RNA-based therapy intended to treat Duchenne patients with exon 51 amenable mutations; and we initiated EMBARK, our global pivotal trial of SRP-9001, the only global trial currently enrolling using a gene therapy micro-dystrophin to treat Duchenne,” stated Doug Ingram, Sarepta’s president and CEO. Mr. Ingram continued, “We entered 2022 in a position of strength, with over $2.1 billion of cash and cash equivalents, total revenue guidance of over $880 million and net product revenue guidance of over $800 million. Further, in the first quarter of 2022, we announced statistically significant functional results and demonstrated a differentiated safety profile for SRP-9001 from Part 2 of Study 102. We are continuing to enroll and dose patients in the EMBARK and MOMENTUM studies, and are...